TENOR CAPITAL MANAGEMENT Co. L.P. Acquires New Stake in Biotech Acquisition (NASDAQ:BIOT)

TENOR CAPITAL MANAGEMENT Co. L.P. acquired a new stake in Biotech Acquisition (NASDAQ:BIOT) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 280,581 shares of the company’s stock, valued at approximately $2,727,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Berkley W R Corp acquired a new stake in Biotech Acquisition in the first quarter valued at $477,000. Atalaya Capital Management LP acquired a new stake in Biotech Acquisition during the 1st quarter worth about $5,402,000. Polar Asset Management Partners Inc. acquired a new stake in Biotech Acquisition during the 1st quarter worth about $5,832,000. Jane Street Group LLC bought a new position in Biotech Acquisition in the 1st quarter valued at about $1,027,000. Finally, Alyeska Investment Group L.P. bought a new position in Biotech Acquisition in the 1st quarter valued at about $875,000. Institutional investors and hedge funds own 22.98% of the company’s stock.

NASDAQ BIOT remained flat at $$9.67 during trading hours on Thursday. 1,199 shares of the company traded hands, compared to its average volume of 35,288. Biotech Acquisition has a twelve month low of $9.54 and a twelve month high of $9.95. The stock’s 50 day simple moving average is $9.69.

Biotech Acquisition Company Profile

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Recommended Story: P/E Growth (PEG)

Want to see what other hedge funds are holding BIOT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biotech Acquisition (NASDAQ:BIOT).

Institutional Ownership by Quarter for Biotech Acquisition (NASDAQ:BIOT)

Receive News & Ratings for Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.